Urodynamix Technologies Ltd.
TSX VENTURE : URO

Urodynamix Technologies Ltd.

February 26, 2007 08:45 ET

Urodynamix Announces Positive Results From NIRS Prostate Study 2

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Feb. 26, 2007) - Urodynamix Technologies Ltd. (TSX VENTURE:URO) today announced positive results from a study ("NIRS Prostate Study 2") carried out at the Bladder Care Center at the University of British Columbia. The results of this study demonstrated that the URO-NIRS prototype can non-invasively characterize bladder function in men with obstruction and lower urinary tract symptoms ("LUTS").

"The study results suggest that NIRS in conjunction with a simple non-invasive uroflow test may help urologists quickly diagnose obstruction caused by prostate disease without subjecting them to conventional, catheter-based urodynamics evaluation," commented Dr. Lynn Stothers, MD, Director of the UBC Bladder Care Center and Principal Investigator.

Based on the study results and subsequent conclusions made by the Company's Medical Advisory Board, Urodynamix believes that NIRS will provide a comfortable, non-invasive alternative to conventional catheter-based urodynamics tests in men with prostate disease and other urological conditions. Based on the study results, URO-NIRS can identify physiological changes and allow physicians to non-invasively monitor bladder function and differentiate between LUTS caused by an enlarged prostate, defined as obstruction, and LUTS caused by a weak or diseased bladder.

"We are very pleased with these positive results, which are in line with our expectations. In this study, NIRS was highly effective at differentiating between normal subjects, obstruction and weak or diseased bladder," said Barry Allen, President and CEO of Urodynamix. "We have now evaluated the performance of the NIRS technology in two different studies in males, and we are confident that our device will offer a valid diagnostic alternative to the physicians treating men in this large and growing group."

Urodynamix believes that the simple, non-invasive NIRS procedure will provide clinically relevant information to aid in the diagnosis and influence the course of treatment for men with LUTS. Further studies are planned to confirm the accuracy of the Company's pattern recognition algorithms.

Prostate Study 2 Results

This clinical study, supported in part by the Industrial Research Assistance Program, was conducted by Drs. Lynn Stothers and Andrew Macnab from October 2006 to January 2007 at the UBC Hospital Bladder Care Centre. The study enrolled 35 male subjects, including 25 pathological subjects with LUTS at risk for obstruction due to prostate disease and 10 healthy normal subjects.

The study identified changes in the NIRS patterns corresponding with physiological changes, allowing the Company to develop a series of algorithms that predict the presence or absence of obstruction in subjects when NIRS is used in conjunction with uroflow versus catheter-based cystometry and uroflow combined (13 equals obstructed, 10 equals normal, 6 equals unobstructed with abnormal flow, 6 equals equivocal). For the study of 34 included subjects, NIRS patterns plus uroflow data accurately predicted the conditions in 23 of 25 pathological subjects and 9 of 9 normal subjects.

This study indicated that pathological subjects exhibited significant bladder activity on average 26.11 seconds (plus/minus 17.50 standard deviations) in advance of recorded uroflow. Normal subjects exhibited bladder activity on average 8.00 seconds (plus/minus 3.13 standard deviations) in advance of recorded uroflow.

Statistical analysis showed that the area under the ROC curve (a plot of the true positive rate against the false positive rate for a diagnostic test) was 0.98, indicating that NIRS provided quantifiable evidence of the presence or absence of obstruction in this study population. NIRS data is collected using a non-invasive self-adhesive light sensor applied directly to the abdomen of the subject prior to voiding.

The data from NIRS Prostate Study 2 corroborate results obtained in a previous study conducted at the UBC Bladder Care Centre (see news release dated July 5, 2006 for details).

About LUTS and Prostate Disease

LUTS, or lower urinary tract symptoms, is a common term used to describe the range of urinary symptoms that may be linked with prostate disease or changes in the bladder caused by neurological disease, stroke, Parkinson's Disease, certain drugs, infections or irritable bladder. The prevalence of LUTS is believed to be as high as 90% in men aged 50 to 80 years old.

LUTS are often associated with an enlarged prostate; however the symptoms alone cannot be used to make a diagnosis since they may reflect the effects of prostate disease as well as functional changes in the bladder. The current diagnosis relies upon the International Prostate Symptom Score questionnaire developed more than a decade ago in combination with urinalysis, serum prostate-specific antigen (PSA) test and digital rectal examination. Invasive pressure-flow urodynamic studies currently offer the only way to differentiate between bladder outlet obstruction and a failing detrusor muscle.

Accurate diagnosis is important to ensure appropriate treatment of the underlying disease. Therapies now available to treat LUTS related to prostate disease include open surgical procedures, transurethral surgical procedures, microwave therapy, and drugs such as alpha blockers or 5-alpha-reductase inhibitors.

About Urodynamix Technologies Ltd.

Urodynamix is developing a portfolio of non-invasive diagnostic products for a variety of large and growing global markets. The Company is currently developing NIRS applications for urinary incontinence in men and women, intra-abdominal hypertension and compartment syndrome, erectile dysfunction and vascular diseases. The Company's disruptive technology has the potential to affect the diagnosis and treatment of more than 200 million people worldwide.

On behalf of the Board,

Barry Allen, President & CEO

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information